Corey J. Langer, MD, outlines the prevalence of BRAF mutations in NSCLC and looked ahead to where the development pipeline of agents for the treatment of patients with BRAF-mutated NSCLC is headed.
Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLC onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Charu Aggarwal, MD, MPH (top), Ronac Mamtani, MD, (bottom left), and Lova Sun, MD. view more
Credit: Penn Medicine
PHILADELPHIA Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the
Abramson Cancer Center at the University of Pennsylvania.
In a new study published online today in
JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated with immunotherapy alone, compared to patients without this mutation. This survival difference by KRAS status was not seen, however, in patients treated with both chemotherapy and immunotherapy, suggesting combination therapy for patients without the mutation may be preferred.